Nuvilex Positioned for Lucrative Deal With Cell-in-a-Box Technology's Diverse Treatments Amid Biotech Frenzy

NEW YORK, NY--(Marketwired - May 20, 2014) - Nuvilex, Inc. (OTCQB: NVLX) is up to much more than most are currently aware of, and it only takes a bit of digging to realize it. The company is clearly out to extend the survival time of patients with advanced inoperable pancreatic cancer in its upcoming Phase 2b clinical trial, but reading the recently changed language in Nuvilex's "About Nuvilex" section of its press releases, and it's also clear they're not stopping there. It is the company's diversity with not only pancreatic cancer, but with other cancers and diabetes, that has it positioned for what could potentially be a lucrative deal with a much larger pharmaceutical firm.

The new language in Nuvilex's press releases reads: Nuvilex is also working towards clinical trials associated with the symptoms of advanced pancreatic cancer and other abdominal cancers.

Abdominal cancer is defined as a type of cancer that occurs when there is an uncontrolled growth of abnormal cells anywhere in the abdomen, the area between the lower chest and the groin. The abdomen consists of many organs, including the stomach, intestines, liver, gallbladder, pancreas, esophagus, and numerous blood vessels. Has Nuvilex stumbled onto something that the company's Cell-in-a-Box^® technology could provide a treatment for in all stomach cancers and not just pancreatic cancer?

Well, another company, OncoMed Pharmaceuticals is currently developing a number of therapies that target cancer stem cell proteins to block their ability to replicate and proliferate progenitor cells. This diverse approach has landed OncoMed several big name biopharmaceutical partners including, GlaxoSmithKline, Bayer, and what may be its biggest partner, Celgene Corp.

Back in December, OncoMed inked a mammoth deal with Celgene. In that deal, Celgene put up $155 Million in upfront payments to OncoMed, purchased $22.5 Million in OncoMed's common stock, and pledged up to $3.3 Billion in milestone payments for the co-marketing rights for up to six of OncoMed's therapies, including demcizumab, and five preclinical therapies.

Demcizumab is a mid-stage product that completed a Phase 1 pancreatic cancer clinical trial combined with Gemzar (gemcitabine), and the pancreatic cancer angle could be why Celgene has not only shown interest but has invested in its future.

With a biotech frenzy, of sorts, underway in 2014, Nuvilex's pancreatic cancer treatment using Cell-in-a-Box^® combined with the anticancer drug ifosfamide may very well prove that it too is a diverse solution to fighting a number of cancers, and if so, having the likes of Celgene as a competitor could also have Celgene ready to get involved with its success much like it's doing with OncoMed.

About Stock Market Media Group
SMMG is a Research and Content Development IR firm offering a platform for corporate stories to unfold in the media with Reports, Interviews and Articles. SMMG is compensated for Nuvilex content by a third party who reserves the right to buy, sell or remain neutral on securities after the publication of this article. SMMG has received total compensation of $87,580 for content related to Nuvilex. Additionally, a principal at SMMG currently owns 200,000 total shares of Nuvilex issued by the company through a consulting agreement which has since ended for work unrelated to content development. The shares have been held for the requisite period under Rule 144 as of April 30, 2013, and are eligible to be sold immediately without further notice. For more information: www.stockmarketmediagroup.com.